

APPENDIX A

**(VERSION OF CLAIMS AS AMENDED HEREIN
WITH MARKINGS TO SHOW CHANGES MADE)**

(Serial No. 10/055,728)

VERSION OF AMENDED CLAIMS
WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

6. (Twice Amended) The method according to claim 1, wherein said at least one marker gene comprises a gene involved in the generation, maintenance and/or breakdown of blood vessels.
7. (Twice Amended) The method according to claim 1, wherein said at least one marker gene comprises a sequence [as depicted in Table 1 or Table 2]selected from the group consisting of SEQ ID NOS:1-31.
8. (Twice Amended) The method according to claim 1, wherein said at least one marker gene comprises a sequence selected from the group consisting of [a sequence depicted in Figure 1 through 18]SEQ ID NOS:65-82 or a part or analogue thereof.
9. (Twice Amended) The method according to claim 1, wherein expression of said at least one marker gene is quantified.
10. (Twice Amended) The method according to claim 1, further comprising comparing expression of said at least one marker gene with a reference value.
11. (Twice Amended) The method according to claim 2, wherein said tumor cell comprises Kaposi's Sarcoma.

12. (Amended) A method of detecting an expression product of a marker gene comprising:
obtaining a sample from an individual;
introducing a nucleic acid to said sample, said nucleic acid selected from the group consisting of [a sequence as depicted in Figure 1-18, a sequence as depicted in Table 1 and a sequence as depicted in Table 2]SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof[to said sample]; and
determining whether said nucleic acid hybridizes in said sample.

13. (Amended) A method of detecting an expression product of a marker gene comprising:
incubating a proteinaceous molecule to a sample from an individual, said proteinaceous molecule capable of specifically binding a protein encoded by a nucleic acid selected from the group consisting of [a sequence as depicted in Figure 1-18, a sequence as depicted in Table 1 and a sequence as depicted in Table 2]SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof;
and
detecting binding between said proteinaceous molecule and said protein.

14. (Twice Amended) The method according to claim 12, further comprising determining the presence of a tumor cell in [an]said individual.

15. (Twice Amended) The method according to claim 12, further comprising determining the presence of a site of angiogenesis in [an]said individual.

16. (Twice Amended) The method according to claim 12, further comprising determining whether a treatment is effective in changing the status of a certain set of target cells in [an]said individual.

18. (Twice Amended) The method according to claim 14, wherein said tumor cell comprises Kaposi's Sarcoma.

20. (Amended) The method according to claim 19, wherein said at least one marker gene comprises a sequence selected from the group consisting of [a sequence as depicted in Figure 1-18, a sequence as depicted in Table 1, a sequence as depicted in Table 2]SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof.

23. (Twice Amended) The method according to claim 21, wherein said marker gene comprises a sequence selected from the group consisting of [a sequence as depicted in Figure 1-18, a sequence as depicted in Table 1, a sequence as depicted in Table 2]SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof.

27. (Twice Amended) The method according to claim 25, wherein said at least one marker gene comprises a sequence selected from the group consisting of [a sequence as depicted in Figure 1-18, a sequence as depicted in Table 1, a sequence as depicted in Table 2]SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof.

31. (Twice Amended) The method according to claim 1, wherein said expression product comprises one of [a TIE 1 sequence, a Saliadhesion or Siglec 1 sequence, a sequence as depicted in Figure 8 or Figure 17]SEQ ID NOS:6, 30, 72 and 81, or a part or analogue thereof.

32. (Amended) A method of detecting angiogenesis comprising detecting peripheral blood mononuclear cell expression of at least one of [Keratin 14 sequence, TIE 1 sequence, a Saliadhesion or Siglec 1 sequence, a sequence as depicted in Figure 2, Figure 8 or Figure 17]SEQ ID NOS:6, 18, 30, 66, 72 and 81, or a part or analogue thereof.

33. (Amended) A method of determining the presence of a tumor cell in an individual comprising:
obtaining a sample from said individual; and
detecting the level of peripheral blood mononuclear cell expression of at least one of [a Keratin 14 sequence, TIE 1 sequence, a Salioadhesion or Siglec 1 sequence, a sequence as depicted in Figure 2, Figure 8 or Figure 17]SEQ ID NOS:6, 18, 30, 66, 72 and 81, or [an]a part or analogue thereof.

34. (Amended) A method of diagnosing presence of disease comprising comparing expression of an isolated sequence of [Keratin 14 sequence, TIE 1 sequence, a Salioadhesion or Siglec 1 sequence, a sequence as depicted in Figure 2, Figure 8 or Figure 17]SEQ ID NOS:6, 18, 30, 66, 72 and 81, or [an]a part or analogue thereof, in an individual to a reference value.

35. (Amended) A diagnostic kit comprising a nucleic acid comprising a sequence selected from the group consisting of [a sequence as depicted in Figures 1-18, Table 1, Table 2]SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof, and a proteinaceous molecule capable of specifically binding a protein encoded by said nucleic acid or said part or analogue thereof.

36. (Amended) The diagnostic kit according to claim 35, further comprising at least one of [a Keratin 14 sequence, a TIE 1 sequence, a Salioadhesion or Siglec 1 sequence, a sequence as depicted in Figure 2, Figure 8 or Figure 17]SEQ ID NOS:6, 18, 30, 66, 72, and 81, or [an]a part or analogue thereof.

39. (Amended) A method for identifying desired drug activity comprising:
determining an expression pattern of a marker gene in cells;
incubating said cells with an expression product of a gene comprising [a sequence as depicted in Figure 1-18, Table 1 or Table 2]one of SEQ ID NOS:1-31 and 65-82; and
detecting an alteration in said expression pattern of said marker gene after said incubating.

40. (Amended) A compound capable of altering the activity of at least one of [Salioadhesion or Siglec 1, TIE 1, Keratin 14]SEQ ID NOS:66, 72, and 81, and the expression of at least one of [Salioadhesion or Siglec 1, TIE 1 and Keratin 14]SEQ ID NOS:66, 72, and 81 in a cell.

41. (Amended) A method of preparing a medicament comprising:
identifying a compound capable of altering the activity of at least one of [Salioadhesion or Siglec 1, TIE 1, Keratin 14]SEQ ID NOS:66, 72, and 81, and the expression of at least one of [Salioadhesion or Siglec 1, TIE 1 and Keratin 14]SEQ ID NOS:66, 72, and 81 in a cell; and
incorporating said identified compound into a medicament.